Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights.

[1]  M. Sabatine,et al.  2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.

[2]  R. Lange,et al.  A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investigator-Initiated trial. , 2016, American heart journal.

[3]  A. Aki,et al.  The SYNTAX score is correlated with long-term outcomes of coronary artery bypass grafting for complex coronary artery lesions. , 2016, Interactive cardiovascular and thoracic surgery.

[4]  L. Mauri,et al.  Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study , 2016, Circulation.

[5]  M. Al-Omran,et al.  Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials , 2015, BMC Surgery.

[6]  V. Roger,et al.  Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. , 2015, Circulation.

[7]  V. Fuster,et al.  Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. , 2013, The lancet. Diabetes & endocrinology.

[8]  S. Garcia,et al.  Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled in randomized clinical trials and observational studies. , 2013, Journal of the American College of Cardiology.

[9]  R. D. de Winter,et al.  Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery: Pathophysiology, Management, and Future Directions , 2013, Annals of surgery.

[10]  P. Erwin,et al.  Dual Anti‐platelet Therapy After Coronary Artery Bypass Grafting: Is There Any Benefit? A Systematic Review and Meta‐Analysis , 2013, Journal of cardiac surgery.

[11]  Antonio Colombo,et al.  Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial , 2013, The Lancet.

[12]  G. Dangas,et al.  Strategies for multivessel revascularization in patients with diabetes. , 2012, The New England journal of medicine.

[13]  C. Jackevicius,et al.  Use of Aspirin and Clopidogrel After Coronary Artery Bypass Graft Surgery , 2012, The Annals of pharmacotherapy.

[14]  A. Haverich,et al.  Aspirin plus Clopidogrel Versus Aspirin Alone After Coronary Artery Bypass Grafting: The Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) Trial , 2011 .

[15]  L. Køber,et al.  Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction. , 2011, Journal of the American College of Cardiology.

[16]  C. Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. , 2011, Journal of the American College of Cardiology.

[17]  S. Yusuf,et al.  Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. , 2010, American heart journal.

[18]  Shengshou Hu,et al.  Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. , 2010, Journal of the American College of Cardiology.

[19]  D. Whellan,et al.  Aspirin and clopidogrel use in the early postoperative period following on-pump and off-pump coronary artery bypass grafting. , 2009, The Journal of thoracic and cardiovascular surgery.

[20]  P. Kolh,et al.  Guideline on antiplatelet and anticoagulation management in cardiac surgery. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[21]  G. Guyatt,et al.  The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[22]  V. Fuster,et al.  Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. , 2008, American heart journal.

[23]  M. Ruel,et al.  Clopidogrel Is Safe Early after On‐ and Off‐pump Coronary Artery Bypass Surgery , 2007, Journal of cardiac surgery.

[24]  S. Yusuf,et al.  Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial , 2004, Circulation.

[25]  S. Steinhubl,et al.  Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. , 2004, The American journal of cardiology.

[26]  D. Mangano.  Aspirin and mortality from coronary bypass surgery. , 2002, The New England journal of medicine.

[27]  E J Topol,et al.  Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. , 1998, Circulation.

[28]  Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy , 1994, BMJ.

[29]  L. Smith,et al.  Influence of diabetes and mammary artery grafting on survival after coronary bypass. , 1991, Circulation.

[30]  J. Barboriak,et al.  Atherosclerosis in aortocoronary bypass grafts. Morphologic study and risk factor analysis 6 to 12 years after surgery. , 1986, Arteriosclerosis.

[31]  S. Wacholder,et al.  The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. , 1984, The New England journal of medicine.

[32]  T. Wagner,et al.  Effect of clopidogrel use post coronary artery bypass surgery on graft patency. , 2014, The Annals of thoracic surgery.

[33]  Samer A M Nashef,et al.  EuroSCORE II. , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[34]  M. Donaldson,et al.  Causes of primary graft failure after in situ saphenous vein bypass grafting. , 1992, Journal of vascular surgery.